Compare XFOR & KOYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XFOR | KOYN |
|---|---|---|
| Founded | 2014 | 2024 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 332.3M | 314.9M |
| IPO Year | N/A | 2025 |
| Metric | XFOR | KOYN |
|---|---|---|
| Price | $3.15 | $10.00 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $34.67 | N/A |
| AVG Volume (30 Days) | ★ 553.0K | 71.5K |
| Earning Date | 11-05-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $33,979,000.00 | N/A |
| Revenue This Year | $1,307.51 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 2925.74 | N/A |
| 52 Week Low | $1.35 | $9.85 |
| 52 Week High | $26.83 | $10.18 |
| Indicator | XFOR | KOYN |
|---|---|---|
| Relative Strength Index (RSI) | 36.99 | N/A |
| Support Level | $3.49 | N/A |
| Resistance Level | $3.90 | N/A |
| Average True Range (ATR) | 0.23 | 0.00 |
| MACD | -0.05 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
CSLM Digital Asset Acquisition Corp III Ltd is a blank check company that acts to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities.